West Nile Screening Is Only First Step To Broader Virus Protection – Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA hopes that efforts to develop a blood screening assay for West Nile virus will lead to technology that can be adapted to screen for other rare, endemic flaviviruses
You may also be interested in...
NAT Mini-Pool Is West Nile Blood Screen Priority, But IgM Role Is Uncertain
FDA is recommending manufacturers of tests that could potentially be used to screen blood for West Nile Virus to pursue nucleic acid test mini-pooling, despite concerns with the procedure's sensitivity
NAT Mini-Pool Is West Nile Blood Screen Priority, But IgM Role Is Uncertain
FDA is recommending manufacturers of tests that could potentially be used to screen blood for West Nile Virus to pursue nucleic acid test mini-pooling, despite concerns with the procedure's sensitivity
CBER Deputy Director Goodman To Assume Biologics Directorship In January
Incoming Center for Biologics Evaluation & Research Director Jesse Goodman, MD, brings a working relationship with blood test manufacturers from his experience as CBER deputy director